Sign In
Buy AYTU
$2.23
+0.0800 (+3.72%)
At Close: Jul 31, 2026
Aytu BioPharma Announces Sale of Consumer Health Business Following Wind Down of Consumer Health Operations
08:00am, Tuesday, 06'th Aug 2024
Consumer Health Wind Down and Sale Maximizes Shareholder Value as Company Focuses on Rx Segment Eliminates Materially All Remaining Expenses Associated with the Consumer Health Business Provides for R
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
08:00am, Tuesday, 18'th Jun 2024
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis poi
Aytu BioPharma, Inc. (AYTU) Q3 2024 Earnings Call Transcript
08:28pm, Wednesday, 15'th May 2024
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q3 2024 Earnings Call Transcript May 15, 2024 4:30 PM ET Company Participants Roger Weiss - Investor Relations Joshua Disbrow - Chief Executive Officer Mark Oki - C
Aytu BioPharma Reports Fiscal 2024 Third Quarter Operational and Financial Results
04:05pm, Wednesday, 15'th May 2024
Q3 2024 ADHD Portfolio net revenue up 49% compared to Q3 2023 Q3 2024 adjusted EBITDA 1 improved by $7.0 million compared to Q3 2023 TTM March 2024 operating income of $7.3 million for the Rx Business
Aytu BioPharma to Report Third Quarter Fiscal 2024 Financial and Operational Results on May 15, 2024
04:15pm, Wednesday, 08'th May 2024
DENVER, CO / ACCESSWIRE / May 8, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its financial
Aytu BioPharma to Present at the Emerging Growth Conference on April 4, 2024
09:00am, Wednesday, 03'rd Apr 2024
Webcasted presentation to take place at 4:40 p.m. Eastern time DENVER, CO / ACCESSWIRE / April 3, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
10:52pm, Wednesday, 14'th Feb 2024
Aytu BioPharma, Inc. (AYTU) Q2 2024 Earnings Call Transcript
Aytu BioPharma Reports Record ADHD Revenue and Operating Income During Fiscal 2024 Second Quarter
04:05pm, Wednesday, 14'th Feb 2024
Q2 2024 operating income of $2.4 million Q2 2024 net loss of $0.2 million and adjusted EBITDA1 of $5.1 million Q2 2024 Rx Segment net revenue of $18.7 million, net income of $0.7 million, and adjusted
Aytu BioPharma to Report Second Quarter Fiscal 2024 Financial and Operational Results on February 14, 2024
04:15pm, Wednesday, 07'th Feb 2024
DENVER, CO / ACCESSWIRE / February 7, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report its finan
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
09:00am, Tuesday, 23'rd Jan 2024
DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Jo
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
08:00am, Thursday, 30'th Nov 2023
Webcasted presentation to take place at 1:10pm ET DENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commerci
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
07:30pm, Tuesday, 14'th Nov 2023
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants N
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
04:05pm, Tuesday, 14'th Nov 2023
Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash ba
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
08:30am, Wednesday, 08'th Nov 2023
Ranked 118th Fastest Growing Company in North America Ranked 23rd Fastest Growing Life Sciences Company DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDA
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
04:15pm, Tuesday, 07'th Nov 2023
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial r
